President Trump's executive order to separate the combined MMR vaccine into individual shots faces significant regulatory and manufacturing challenges, with FDA approval potentially taking up to 10 years. Merck and GSK, the only licensed producers of the combined MMR vaccine, have not manufactured individual vaccines for decades and cite lack of scientific support for the split. Meanwhile, IBM is enhancing its AI capabilities by integrating OpenAI models like GPT-5.6 into its consulting platform, aiming to advance enterprise AI and cybersecurity solutions. Jack in the Box is showing early signs of operational improvement under interim leadership but continues to face challenges in a tough quick-service restaurant market. Additionally, investor Michael Burry is increasing short positions on several tech stocks, citing overvaluations after recent rallies.
